This bill would require the US Postal Service to extend sales of its Alzheimer’s semipostal stamp for an additional six years. The stamp has been sold since November 30, 2017 and would normally be discontinued on November 30, 2019. The purpose of the Alzheimer’s semipostal stamp is to raise funds for Alzheimer’s research, with proceeds from the sale of the stamp going to the National Institutes of Health (NIH) to conduct medical research relating to Alzheimer’s. The bill states that the purpose of extending the sale of this stamp is to allow the public to continue contributing to Alzheimer’s research in a convenient way.
Semipostal stamps are sold to the public to raise funds for an identified cause. As of October 2019, the US Postal Service sells two semipostal stamps, one for breast cancer research and the other for Alzheimer’s research. The Alzheimer’s stamp was the first stamp to be released by the US Postal Service under the Semipostal Authorization Act (Public Law 106-253). The semipostal program, over which the Postal Service has discretionary power, states that five stamps will be released over a ten-year period, with each stamp being sold for no more than two years; this bill would supersede that limitation to allow the Postal Service to continue selling additional semipostal stamps. Since the introduction of the 2017 Alzheimer’s stamp through July 2019, a total of $953,000 has been raised through the sale of 7.1 million stamps. A new stamp for post-traumatic stress disorder will be issued in 2019.